2015
Prognostic utility of myocardial blush grade after PCI in patients with NSTE‐ACS: Analysis from the ACUITY trial
Ng VG, Lansky AJ, Toro S, Parise H, Cristea E, Mehran R, Stone GW. Prognostic utility of myocardial blush grade after PCI in patients with NSTE‐ACS: Analysis from the ACUITY trial. Catheterization And Cardiovascular Interventions 2015, 88: 215-224. PMID: 25641255, DOI: 10.1002/ccd.25865.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAgedChi-Square DistributionCoronary AngiographyCoronary CirculationCoronary VesselsFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMultivariate AnalysisMyocardial Perfusion ImagingNon-ST Elevated Myocardial InfarctionOdds RatioPercutaneous Coronary InterventionPredictive Value of TestsProportional Hazards ModelsRisk AssessmentRisk FactorsTreatment OutcomeConceptsMyocardial blush gradePercutaneous coronary interventionST-segment elevation myocardial infarctionNSTE-ACS patientsComposite ischemiaMBG 0/1Non-ST segment elevation acute coronary syndromesSegment elevation acute coronary syndromesElevation acute coronary syndromeFinal myocardial blush gradeIndependent angiographic core laboratoryNet adverse clinical eventsNon-CABG major bleedingNormal epicardial flowOutcomes of patientsTIMI 3 flowAcute coronary syndromeIschemia-driven revascularizationAdverse clinical eventsElevation myocardial infarctionNormal myocardial perfusionAngiographic core laboratoryHigh rateACUITY trialMajor bleeding
2013
The prognostic importance of left ventricular function in patients with ST-segment elevation myocardial infarction: the HORIZONS-AMI trial
Ng VG, Lansky AJ, Meller S, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie B, Shah R, Mehran R, Stone GW. The prognostic importance of left ventricular function in patients with ST-segment elevation myocardial infarction: the HORIZONS-AMI trial. European Heart Journal Acute Cardiovascular Care 2013, 3: 67-77. PMID: 24562805, PMCID: PMC3932775, DOI: 10.1177/2048872613507149.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntithrombinsCoronary AngiographyDrug-Eluting StentsElectrocardiographyFemaleFollow-Up StudiesGated Blood-Pool ImagingHirudinsHumansMaleMiddle AgedMyocardial InfarctionPeptide FragmentsPercutaneous Coronary InterventionPrognosisProspective StudiesRecombinant ProteinsTreatment OutcomeVentricular Function, LeftConceptsST-segment elevation myocardial infarctionLeft ventricular ejection fractionPaclitaxel-eluting stentsHORIZONS-AMI trialElevation myocardial infarctionLV dysfunctionLV functionMyocardial infarctionIschaemia-driven target lesion revascularizationMajor adverse cardiovascular eventsNet adverse clinical eventsPrimary percutaneous coronary interventionBaseline LV dysfunctionIndex revascularization procedureAdverse cardiovascular eventsOutcomes of patientsTarget lesion revascularizationHigh-risk patientsSubstantial clinical benefitAdverse clinical eventsNormal LV functionPercutaneous coronary interventionVentricular ejection fractionLeft ventricular functionBare metal stents
2012
Long-Term Prognosis of Patients Presenting With ST-Segment Elevation Myocardial Infarction With No Significant Coronary Artery Disease (from The HORIZONS-AMI Trial)
Larsen AI, Nilsen DW, Yu J, Mehran R, Nikolsky E, Lansky AJ, Caixeta A, Parise H, Fahy M, Cristea E, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Stone GW. Long-Term Prognosis of Patients Presenting With ST-Segment Elevation Myocardial Infarction With No Significant Coronary Artery Disease (from The HORIZONS-AMI Trial). The American Journal Of Cardiology 2012, 111: 643-648. PMID: 23261001, DOI: 10.1016/j.amjcard.2012.11.011.Peer-Reviewed Original ResearchConceptsST-segment elevation myocardial infarctionSignificant coronary artery diseaseCoronary artery diseaseElevation myocardial infarctionArtery diseaseMyocardial infarctionGreater left ventricular ejection fractionMajor adverse cardiovascular eventsNet adverse clinical eventsAcute Myocardial Infarction trialObstructive coronary artery diseaseLeft ventricular ejection fractionLower body mass indexBaseline coronary angiogramAdverse cardiovascular eventsCoronary artery bypassMyocardial Infarction trialNormal coronary arteriesOutcomes of patientsAdverse clinical eventsPrognosis of patientsVentricular ejection fractionBody mass indexQuantitative coronary angiographyRate of death
2011
Radial access in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty in acute myocardial infarction: the HORIZONS-AMI trial.
Généreux P, Mehran R, Palmerini T, Caixeta A, Kirtane AJ, Lansky AJ, Brodie BR, Witzenbichler B, Mockel M, Guagliumi G, Peruga JZ, Dudek D, Fahy MP, Dangas G, Stone GW. Radial access in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty in acute myocardial infarction: the HORIZONS-AMI trial. EuroIntervention 2011, 7: 905-16. PMID: 22157475, DOI: 10.4244/eijv7i8a144.Peer-Reviewed Original ResearchConceptsST-segment elevation myocardial infarctionPrimary percutaneous coronary interventionPrimary PCIHORIZONS-AMI trialElevation myocardial infarctionMajor bleedingMyocardial infarctionTF approachMajor adverse cardiovascular eventsNet adverse clinical eventsAdverse cardiovascular eventsEvent-free survivalAdverse clinical eventsPercutaneous coronary interventionImproved clinical outcomesAcute myocardial infarctionOne-year ratesRate of deathPaucity of dataComposite deathHORIZONS-AMICardiovascular eventsPrimary angioplastyAnticoagulation regimensCoronary interventionImpact of baseline thrombocytopenia on the early and late outcomes after ST-elevation myocardial infarction treated with primary angioplasty: Analysis from the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial
Hakim DA, Dangas GD, Caixeta A, Nikolsky E, Lansky AJ, Moses JW, Claessen B, Sanidas E, White HD, Ohman EM, Manoukian SV, Fahy M, Mehran R, Stone GW. Impact of baseline thrombocytopenia on the early and late outcomes after ST-elevation myocardial infarction treated with primary angioplasty: Analysis from the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial. American Heart Journal 2011, 161: 391-396. PMID: 21315224, DOI: 10.1016/j.ahj.2010.11.001.Peer-Reviewed Original ResearchConceptsST-elevation myocardial infarctionPrimary percutaneous coronary interventionBaseline thrombocytopeniaMajor cardiac eventsPercutaneous coronary interventionMyocardial infarctionMajor bleedingPrimary angioplastyCardiac eventsCoronary interventionLate outcomesNet adverse clinical eventsAcute Myocardial Infarction trialHORIZONS-AMI trialMajor cardiovascular eventsMyocardial Infarction trialOutcomes of patientsAcute coronary syndromeAdverse clinical eventsEarly adverse eventsAcute myocardial infarctionHarmonizing OutcomesCardiovascular eventsCoronary syndromeAdverse events
2009
Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial
Mehran R, Lansky AJ, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Wong SC, Nikolsky E, Gambone L, Vandertie L, Parise H, Dangas GD, Stone GW, Investigators F. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. The Lancet 2009, 374: 1149-1159. PMID: 19717185, DOI: 10.1016/s0140-6736(09)61484-7.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAngioplasty, Balloon, CoronaryAnticoagulantsFemaleFollow-Up StudiesHemorrhageHeparinHirudinsHumansKaplan-Meier EstimateMaleMiddle AgedMyocardial InfarctionPeptide FragmentsPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexProportional Hazards ModelsRecombinant ProteinsStentsSurvival RateThrombosisTreatment OutcomeConceptsGlycoprotein IIb/IIIa inhibitorsST-segment elevation myocardial infarctionNet adverse clinical eventsPercutaneous coronary interventionAdverse clinical eventsBivalirudin groupMajor bleedingClinical eventsControl groupMyocardial infarctionAcute ST-segment elevation myocardial infarctionIIb/IIIa inhibitorsPrimary percutaneous coronary interventionHORIZONS-AMI trialMajor haemorrhagic complicationsPrimary trial endpointRate of MACERate of NACEElevation myocardial infarctionOnset of symptomsAcute myocardial infarctionOptimum treatment strategyWithdrawal of consentThrombin inhibitor bivalirudinImportant clinical implications